NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary Chia Tai Tianqing has further deepened its exclusive strategic partnership with GlaxoSmithKline (GSK), obtaining the commercialisation rights for two flagship innovative respiratory drugs of GSK in mainland China: Trelegy Ellipta® (fluticasone furoate/umeclidinium bromide/vilanterol powder for inhalation) and Anoro Ellipta® (umeclidinium bromide/vilanterol powder for inhalation). All sales revenue generated from the two products will be recognised as operating revenue of Chia Tai Tianqing.
NewTimeSpace News: On 8 July 2026, BIDU-SW(09888.HK) trended upward during morning trading. As of 11:35, the stock was quoted at HK$116.6, up 5.42%. Overseas research institute AutnmyAI released a global ranking of overall Robotaxi competitiveness, with Baidu Apollo Go claiming the top spot by composite score worldwide.
Recently, Mythological Accident Emergency Response Office, one of China's first batch of AI-native animated theatrical films, started filming in Wenzhou, Zhejiang. Among a crowd of film and television producers, Mininglamp Technology (2718.HK) joined the crew as the "AI Coordinator," becoming a participant in this AI movie production.
NewTimeSpace News: InSilico Medicine Cayman TopCo (03696.HK) announced on 8 July that Rentosertib (ISM001-055), an AI-driven TNIK small-molecule inhibitor, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The trial plans to enrol 320 subjects across 47 clinical centres nationwide, with the primary endpoint being the annual rate of decline in forced vital capacity within 52 weeks. The asset has previously obtained FDA Orphan Drug Designation and NMPA Breakthrough Therapy Designation. The Company cautions uncertainties over business development.
NewTimeSpace News: Jenscare Scientific Co., Ltd. (09877.HK) announced on 8 July that its self-developed LuX-Valve Plus transcatheter tricuspid valve replacement system has obtained EU MDR CE certification, making it the world’s second approved in-situ transcatheter tricuspid valve replacement product. Over 1,000 clinical implantations have been completed across dozens of countries and regions on five continents globally. The device has received FDA Breakthrough Device designation and entered NMPA’s Special Review Procedure for Innovative Medical Devices. The Company cautions that there is no guarantee of successful product launch and commercialisation.
NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals Co.,Ltd (01276.HK) announced that its subsidiary Suzhou Shengdiya Biopharmaceuticals has received the Drug Clinical Trial Approval Letter for SHR-4685 Injection issued and approved by the National Medical Products Administration (NMPA), authorising monotherapy clinical trials of the product in patients with advanced solid tumours. This innovative anti-tumour drug is independently developed by the Group, and no similar drugs have been approved for marketing at home or abroad to date.
NewTimeSpace News: Mabwell (Shanghai) Bioscience Co., Ltd. (02493.HK) announced that the clinical trial application for 9MW5211 Injection indicated for Type 1 Diabetes Mellitus (T1DM) has been approved by the National Medical Products Administration (NMPA). Previously, its clinical trial application for Inflammatory Bowel Disease (IBD) was granted approval by both NMPA and the U.S. Food and Drug Administration (FDA), while the application for Multiple Sclerosis (MS) also obtained NMPA clearance.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the Phase II clinical trial of self-developed SYH2070 Injection for the treatment of mixed hyperlipidaemia has officially kicked off at the first clinical centre in China. As an siRNA drug targeting ANGPTL3 mRNA, the candidate delivers sustained and stable reduction of triglycerides and low-density lipoprotein cholesterol simultaneously.
NewTimeSpace News: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK) announced that it has formally signed a cooperation agreement to jointly build a Joint Laboratory for AI-Driven Drug Discovery with the Frontier Interdisciplinary Research Center of HUST-CityU Advanced Research Institute. The two parties will carry out in-depth cooperation focusing on antibody discovery and molecular design to jointly establish a new generation AI-powered innovative drug research and development paradigm.
On July 7, 2026, Hong Kong stocks pared early gains to close lower. Performance across the AI and large model industry chains was mixed. Tencent Holdings rose 2.0% following the official release of its next-generation large model, Hunyuan Hy3, and a share repurchase worth HK$205 million. Meituan-W climbed 4.5% as LongCat-2.0 was officially open-sourced and successfully adapted by Moore Threads. Zhipu grew 5.2% upon completing its A-share IPO tutoring phase and recently launching the ZCode programming agent. On the other hand, Kuaishou-W plummeted 12.0%, and SenseTime-W slid 6.7%.
NewTimeSpace (newtimespace.com) reported that on July 7, 2026, the chip theme traded actively, with HUA HONG GRACE (01347.HK) surging then pulling back. As of 13:30, the stock was quoted at HKD 181.600, up 2.02%.
NewTimeSpace (newtimespace.com) reported that on July 7, 2026, the humanoid robot theme weakened, with Midea Group (00300.HK) fluctuating slightly lower. As of 13:11, the stock was quoted at HKD 87.650, down 0.79%.
NewTimeSpace News: Zhaoke Ophthalmology Limited (06622.HK) announced that YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution), its innovative drug for presbyopia, was approved by Hainan Provincial Medical Products Administration on 26 June 2026 for use as an urgently needed clinically imported drug at Boao Super Hospital. It marks the first innovative therapy approved in China for the treatment of presbyopia.
On July 6, Hong Kong stocks trended higher, though the LLM supply chain faced severe divergence. Hit by news of Nvidia's NVL144 rack deployments being delayed to 2028 due to PCB manufacturing hurdles, AI hardware stocks plummeted, while KNOWLEDGE ATLAS plunged nearly 15%. Conversely, AI application players demonstrated strength: Tencent rose 4.8% following the launch of its MoE-based Hunyuan Hy3 model, competitive API pricing, and clear WeChat Agent commercialization prospects, while Kuaishou jumped 8% as Kling AI initiated independent commercialization. On the regulatory front, five departments issued interim measures governing AI personified interactive services, prompting Doubao and Qwen to deprecate user-customized agents, signaling a compliance-driven restructuring of product matrices.
NewTimeSpace (newtimespace.com) reported that Hong Kong semiconductor stocks weakened, with ASMPT (00522.HK) fluctuating lower. As of 14:26, the stock was quoted at HKD 195.200, down 4.69%.
NewTimeSpace (newtimespace.com) reported that on July 6, 2026, the humanoid robot theme fluctuated lower, while Xiaomi Corporation-W (01810.HK) bucked the trend and moved higher. As of 14:03, the stock was quoted at HKD 23.300, up 1.48%.
